CIK 0001348362
- Non-accelerated filer
- Smaller reporting company
Lexaria Bioscience Corp.
Sign in to watch- Ticker
- LEXX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Aug 31
- Incorporated
- NV
- Entity type
- Operating
- EIN
- 202000871
- Phone
- +1 250-765-6424
- Business address
- 100 - 740 MCCURDY ROAD, KELOWNA, British Columbia, Canada, V1X 2P7
- Former names
- Lexaria Corp., LEXARIA CORP.
- 4 Open-market buy CEO bought 7,000 shares at an average $0.13 ($900)
- 4 Open-market buy CEO bought 32,500 shares at an average $0.13 ($4,368)
- 4 Open-market buy CEO bought 8,990 shares at $0.15 ($1,357)
- 4 Open-market buy CEO bought 20,000 shares at an average $0.17 ($3,325)
- 4 Open-market buy CEO bought 3,500 shares at $0.20 ($700)
- 4 Open-market buy CEO bought 26,000 shares at an average $0.22 ($5,697)
- 4 Grant or award Director acquired 10,000 shares (grant or award)
- 4 Grant or award President acquired 55,000 shares (grant or award)
- 4 Open-market buy CEO bought 5,000 shares at an average $0.22 ($1,075)
- 4 Grant or award CEO acquired 1,073,834 shares (grant or award)
- 4 Grant or award Director acquired 20,000 shares (grant or award)
- 4 Grant or award CFO acquired 14,125 shares (grant or award)
- 4 Open-market buy CEO bought 5,000 shares at $0.20 ($975)
- 4 Open-market buy CEO bought 4,000 shares at an average $0.20 ($799)
- 4 Open-market buy CEO bought 20,000 shares at an average $0.19 ($3,820)
- 4 Open-market buy CEO bought 20,000 shares at an average $0.19 ($3,855)
- 4 Open-market buy CEO bought 3,500 shares at an average $0.21 ($725)
- 4 Open-market buy CEO bought 29,500 shares at an average $0.21 ($6,286)
- 4 Open-market buy CEO bought 4,000 shares at an average $0.23 ($934)
- 4 Open-market buy Director bought 100,000 shares at $0.19 ($19,000)
Page 9 of 21 · 420 filings